The Property with Adsorption and Slow Release of Carbon Nanoparticles Suspension Injection for Epirubicin Solution in Vitro_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YANG Qian , CHEN Jie , TIAN Chunxiang , WANG Rong , FAN XueJiao , LU Qing

Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;

Corresponding author：

Keywords：

Carbon nanoparticles suspension injection; Epirubicin; Combination ratio

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To determine the best matching concentration of carbon nanoparticles suspension injection adsorb epirubicin by measuring the combination ratio of carbon nanoparticles suspension injection combined with epirubicin under different matching conditions. And then, to prove the adsorbability of carbon nanoparticles suspension injection adsorb epirubicin in vitro.
Methods 　Firstly, epirubicin-carbon suspension of different concentrations will be prepared. The second, high performance liquid chromatography mass spectrometry（LC-MS） was used to assay the concentration of free epirubicin, and calculate the content of epirubicin that was combinated with carbon nanoparticles suspension injection. The difference of the ratio of carbon nanoparticles suspension injection combined with epirubicin under different matching conditions will be compared in the end.
Results 　The combination ratio of carbon nanoparticles suspension injection combined with epirubicin solution of 5, 10, and 15 mg/ml were 85.6%, 85.7%, and 31.8%, respectively.
Conclusions 　The adsorbability of carbon nanoparticles suspension injection adsorb epirubicin is favourable in vitro. Best matching concentration of carbon nanoparticles suspension injection adsorb epirubicin may be epirubicin solution of 5-10 mg/ml.

Citation： YANG Qian,CHEN Jie,TIAN Chunxiang,WANG Rong,FAN XueJiao,LU Qing,.. The Property with Adsorption and Slow Release of Carbon Nanoparticles Suspension Injection for Epirubicin Solution in Vitro. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2012, 19(7): 739-742. doi: Copy

1.	Cocconi G， Di Blasio B， Boni C， et al. Randomized trial comparing cyclophosphamide， methotrexate， and 5-fluorouracil (CMF) with rotational CMF， epirubicin and vincristine as primary chemotherapy in operable breast carcinoma [J]. Cancer， 2002，95(2)：228-235.
2.	Burnell M， Levine MN， Chapman JA， et al. Cyclophosphamide，epirubicin， and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer [J]. J Clin Oncol， 2010，28(1)：77-82.
3.	Poole CJ， Earl HM， Hiller L， et al. Epirubicin and cyclophosphamide，methotrexate， and fluorouracil as adjuvant therapy for early breast cancer [J]. N Engl Med， 2006， 355(18)：1851-1862.
4.	Overgaard J， Bartelink H. Breast cancer survival advantage with radiotherapy [J]. Lancet， 2000， 356(9237)：1269-1270.
5.	Ragaz J， Jackson SM， Le N， et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer [J]. N Eng J Med， 1997， 337(14)：956-962.
6.	Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomised trials [J]. N Engl J Med， 1995， 333(22)：1444-1455.
7.	Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer：an overview of the randomised trials [J].Lancet， 2000， 355(9217)：1757-1770.
8.	Kegel FS， Rietman BM， Verliefde AR， et al. Reverse osmosis followed by activated carbon filtration for efficient removal of organic micropollutants from river bank filtrate [J]. Water Sci Technol， 2010， 61(10)：2603-2610.
9.	Bu L， Wang K， Zhao QL， et al. Characterization of dissolved organic matter during landfill leachate treatment by sequencing batch reactor， aeration corrosive cell-Fenton， and granular activated carbon in series [J]. J Hazard Mater， 2010， 179 (1-3)：1096-1105.
10.	Sze MF， McKay G. An adsorption diffusion model for removal of para-chlorophenol by activated carbon derived from bituminous coal [J]. Environmental Pollution， 2010， 158(5)：1669-1674.
11.	Yokota T， Saito T， Narushima Y， et al. Lymph-node staining with activated carbon CH40：a new method for axillary lymph-node dissection in breast cancer [J]. Can J Surg， 2000， 43 (3)：191-196.
12.	Sledge G， Neuberg D， Bermardo P， et al. Phase Ⅲ trial of doxorubicin，paclitaxel， and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer：an intergroup trial (E1193) [J]. J Clin Oncol， 2003， 21(4)：588-592.
13.	黄福才. 表阿霉素为主的新辅助化疗治疗局部晚期乳腺癌临床研究 [J]. 吉林医学， 2011， 32(7)：1303-1304.
14.	贾卫娟，张崇建，周婕，等. 高剂量表阿霉素联合环磷酰胺和氟尿嘧啶治疗乳腺癌的临床研究 [J/CD]. 中华普通外科学文献( 电子版)， 2011， 5(4)： 289-293.
15.	曲洪澜，王丽娟，关琦. 紫杉醇与表阿霉素联合治疗晚期乳腺癌的临床观察 [J] . 临床肿瘤学杂志， 2003， 8(5)：345-347.
16.	刘鹏，杨德启，乔新民，等. 长春瑞滨联合表阿霉素新辅助化疗治疗乳腺癌的临床观察 [J]. 中华普通外科杂志， 2004，19(12)：735-737.
17.	Hagiwara A， Takahashi T， Sawai K， et al. Selective drug delivery to peri-tumoral region and regionallymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer—— a pilot study [J]. Anti cancer Drugs， 1997， 8(7)：666-670.
18.	Hagiwara A， Takahashi T， Iwamoto A， et al. Affinity of intraperitoneally injected activated carbon particles adsorbing mitomycin C to tumor surface of Yoshida sarcoma [J]. Anticancer Drug Des， 1990， 5(4)：359-369.

1. Cocconi G， Di Blasio B， Boni C， et al. Randomized trial comparing cyclophosphamide， methotrexate， and 5-fluorouracil (CMF) with rotational CMF， epirubicin and vincristine as primary chemotherapy in operable breast carcinoma [J]. Cancer， 2002，95(2)：228-235.
2. Burnell M， Levine MN， Chapman JA， et al. Cyclophosphamide，epirubicin， and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer [J]. J Clin Oncol， 2010，28(1)：77-82.
3. Poole CJ， Earl HM， Hiller L， et al. Epirubicin and cyclophosphamide，methotrexate， and fluorouracil as adjuvant therapy for early breast cancer [J]. N Engl Med， 2006， 355(18)：1851-1862.
4. Overgaard J， Bartelink H. Breast cancer survival advantage with radiotherapy [J]. Lancet， 2000， 356(9237)：1269-1270.
5. Ragaz J， Jackson SM， Le N， et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer [J]. N Eng J Med， 1997， 337(14)：956-962.
6. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomised trials [J]. N Engl J Med， 1995， 333(22)：1444-1455.
7. Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer：an overview of the randomised trials [J].Lancet， 2000， 355(9217)：1757-1770.
8. Kegel FS， Rietman BM， Verliefde AR， et al. Reverse osmosis followed by activated carbon filtration for efficient removal of organic micropollutants from river bank filtrate [J]. Water Sci Technol， 2010， 61(10)：2603-2610.
9. Bu L， Wang K， Zhao QL， et al. Characterization of dissolved organic matter during landfill leachate treatment by sequencing batch reactor， aeration corrosive cell-Fenton， and granular activated carbon in series [J]. J Hazard Mater， 2010， 179 (1-3)：1096-1105.
10. Sze MF， McKay G. An adsorption diffusion model for removal of para-chlorophenol by activated carbon derived from bituminous coal [J]. Environmental Pollution， 2010， 158(5)：1669-1674.
11. Yokota T， Saito T， Narushima Y， et al. Lymph-node staining with activated carbon CH40：a new method for axillary lymph-node dissection in breast cancer [J]. Can J Surg， 2000， 43 (3)：191-196.
12. Sledge G， Neuberg D， Bermardo P， et al. Phase Ⅲ trial of doxorubicin，paclitaxel， and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer：an intergroup trial (E1193) [J]. J Clin Oncol， 2003， 21(4)：588-592.
13. 黄福才. 表阿霉素为主的新辅助化疗治疗局部晚期乳腺癌临床研究 [J]. 吉林医学， 2011， 32(7)：1303-1304.
14. 贾卫娟，张崇建，周婕，等. 高剂量表阿霉素联合环磷酰胺和氟尿嘧啶治疗乳腺癌的临床研究 [J/CD]. 中华普通外科学文献( 电子版)， 2011， 5(4)： 289-293.
15. 曲洪澜，王丽娟，关琦. 紫杉醇与表阿霉素联合治疗晚期乳腺癌的临床观察 [J] . 临床肿瘤学杂志， 2003， 8(5)：345-347.
16. 刘鹏，杨德启，乔新民，等. 长春瑞滨联合表阿霉素新辅助化疗治疗乳腺癌的临床观察 [J]. 中华普通外科杂志， 2004，19(12)：735-737.
17. Hagiwara A， Takahashi T， Sawai K， et al. Selective drug delivery to peri-tumoral region and regionallymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer—— a pilot study [J]. Anti cancer Drugs， 1997， 8(7)：666-670.
18. Hagiwara A， Takahashi T， Iwamoto A， et al. Affinity of intraperitoneally injected activated carbon particles adsorbing mitomycin C to tumor surface of Yoshida sarcoma [J]. Anticancer Drug Des， 1990， 5(4)：359-369.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The Property with Adsorption and Slow Release of Carbon Nanoparticles Suspension Injection for Epirubicin Solution in Vitro

Abstract Full text Figures/Tables Video References Cited by

Format

Content